430 related articles for article (PubMed ID: 19020197)
21. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
22. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
24. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
25. Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant.
Acero-Bedoya S; Wozniak PS; Sánchez PJ; Ramilo O; Mejias A
Am J Perinatol; 2019 Jul; 36(S 02):S63-S67. PubMed ID: 31238362
[TBL] [Abstract][Full Text] [Related]
26. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.
Murray J; Saxena S; Sharland M
Arch Dis Child; 2014 May; 99(5):469-73. PubMed ID: 24464977
[TBL] [Abstract][Full Text] [Related]
27. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha I; McKoy N
Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
[TBL] [Abstract][Full Text] [Related]
28. Palivizumab: where to from here?
Georgescu G; Chemaly RF
Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
[TBL] [Abstract][Full Text] [Related]
29. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
30. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
31. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
Zembles TN; Gaertner KM; Gutzeit MF; Willoughby RE
Am J Health Syst Pharm; 2016 Mar; 73(6):405-8. PubMed ID: 26953285
[TBL] [Abstract][Full Text] [Related]
32. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
33. [Respiratory syncytial immunoprophylaxis with palivizumab].
De Halleux V; Lombet J; Rigo J
Rev Med Liege; 2007; 62(5-6):299-302. PubMed ID: 17725198
[TBL] [Abstract][Full Text] [Related]
34. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
[No Abstract] [Full Text] [Related]
35. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
Huang K; Wu H
Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.
Blake SM; Tanaka D; Bendz LM; Staebler S; Brandon D
Adv Neonatal Care; 2017 Aug; 17(4):292-298. PubMed ID: 27926583
[TBL] [Abstract][Full Text] [Related]
37. Respiratory syncytial virus infection: clinical features, management, and prophylaxis.
Greenough A
Curr Opin Pulm Med; 2002 May; 8(3):214-7. PubMed ID: 11981311
[TBL] [Abstract][Full Text] [Related]
38. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
[TBL] [Abstract][Full Text] [Related]
39. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
40. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]